Clinical Progress

Atezolizumab: A Quick Look at Its R&D Progress and Clinical Results from the 2024 AACR

18 April 2024
4 min read

Treatment (tx) for advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) includes a combination of surgery, radiation and/or chemotherapy followed by monitoring for local recurrence/distant metastases as standard of care. Given poor outcomes, there remains a clear unmet need in this pt population. On April 5, 2024, the latest clinical trial of Atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk LA SCCHN were reported in 2024 AACR.

Atezolizumab's R&D Progress

Atezolizumab is a monoclonal antibody drug that targets PDL1 and is used in the treatment of various diseases. The drug is primarily used in the field of biomedicine and has shown efficacy in treating neoplasms, digestive system disorders, respiratory diseases, skin and musculoskeletal diseases, urogenital diseases, and other diseases. 

According to the Patsnap Synapse, Atezolizumab has been approved for use in the United States and China. And the clinical trial distributions for Atezolizumab are primarily in the United States, China and United Kingdom. The key indication is Neoplasms. 

Detailed Clinical Result of Atezolizumab

This randomized, parallel assignment, quadrupled-masked phase 3 study (NCT03452137) was aimed to evaluate the efficacy and safety of atezo in pts with LA SCCHN who are at high-risk for disease progression following multi-modal definitive tx.  

In this study, eligible pts with LA SCCHN (Stage IVa or IVb involving the oral cavity, larynx, hypopharynx, HPV negative oropharynx or Stage III HPV positive oropharynx [per AJCC 8th edition]) with no disease progression after multi-modal definitive tx were randomized (1:1) to receive atezo 1200 mg or placebo. Tx was given every 3 weeks for 1 year or until disease progression, unacceptable toxicity or consent withdrawal. Primary endpoint: investigator-assessed event-free survival (INV-EFS). Other key endpoints: overall survival (OS, secondary for efficacy) and safety.

The result showed that a total of 406 pts were randomized to receive either atezo (n=203) or placebo (n=203). 156 (38.4%) pts underwent surgery as part of definitive tx. At clinical cutoff (27 September 2023), median follow-up was 46.5 months (mos). Median INV-EFS was 59.5 mos with atezo vs 52.7 mos with placebo (HR, 0.94; 95% CI, 0.70-1.26). INV-EFS results were generally consistent across all subgroups. OS showed no difference between arms for atezo vs placebo.

It can be concluded that this study did not meet the primary endpoint of INV-EFS, a numerical improvement in INV-EFS was observed for atezo in pts with LA SCCHN, but this was not statistically significant. Atezo was generally well tolerated, and no new safety signals were identified.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

What is Berlin Patient?
"What" Series
2 min read
What is Berlin Patient?
18 April 2024
The "Berlin Patient" refers to Timothy Ray Brown, an American man who was known as the first person to be cured of HIV/AIDS.
Read →
An analysis of ASKC202's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
An analysis of ASKC202's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
18 April 2024
On April 5, 2024, the AACR reported the latest clinical trial results of ASKC202, illustrating its potential clinical benefits and setting the stage for further exploration.
Read →
What is Recurrence-free Survival?
"What" Series
2 min read
What is Recurrence-free Survival?
17 April 2024
Recurrence-free survival (RFS) is a clinical endpoint used in oncology to measure the effectiveness of cancer treatments.
Read →
What is the difference between EMA and HMA?
"What" Series
2 min read
What is the difference between EMA and HMA?
17 April 2024
EMA (European Medicines Agency) and HMA (Heads of Medicines Agencies) are two distinct organizations that play vital roles in the regulation of medicinal products, but their functions and scopes differ.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.